Some genetics experts felt the event raised awareness of the importance of testing, while others had mixed feelings amid growing healthcare access worries.

The firm voluntarily retracted the BLA amid an effort to reprioritize its pipeline and is looking for partners to advance the program.

NEW YORK – Ataraxis AI on Thursday said it will collaborate with Medica Scientia Innovation Research (MEDSIR) to further validate the ability of its artificial intelligence-based digital pathology ...

NEW YORK – Takeda on Wednesday said it was discontinuing its cell therapy business and seeking partners for its cell therapy development platform and preclinical programs. The firm said it currently ...

The firm's lead candidate is a preclinical gene therapy for dry AMD, which it is advancing into IND-enabling studies.

NEW YORK – Sapienza University, Takis Biotech, and liquid biopsy company Tethis said on Friday they are teaming up to develop HER3-targeted therapies and companion diagnostics for lung cancer, with ...

Galapagos is collecting bids for its cell therapy business, and its board will announce its decision on selling the business by Nov. 5.

The firm will use the funding to launch its T-cell engager candidate into clinical trials early next year in LY6G6D-expressing colorectal cancer.

Investigators are assessing whether treatment with the angiotensinogen-targeting RNAi agent reduces patients' risk of cardiovascular disease.

The drugmaker has launched an international Phase I trial, dubbed Breakfree-2, in seven countries to test the autologous therapy.

Patients with HER2-positive tumors fared better on neoadjuvant Enhertu followed by chemo and a dual anti-HER2 antibody regimen than those on standard treatment.

The new biotech is developing an antibody-oligo conjugate platform that uses "brain shuttles" to deliver drugs across the blood-brain barrier.